- Product revenue up 15%, compared to the June 2017
quarter
- Prescriptions filled were up 42% over last year and up
14% over the June 2017 quarter to 19,660
- EBITDA loss reduced to $2.3 million
- Cash on hand equals $10 million
Conference Call Begins at 4:30pm EST
TodaySlide Presentation to Review in Tandem with
Earnings Call Available at
http://ir.sonomapharma.com/events.cfm
Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA, warrants SNOAW), a
specialty pharmaceutical company that develops and markets unique
and effective solutions for the treatment of dermatological
conditions and advanced tissue care, today announced financial
results for the second quarter of fiscal year 2018, ended September
30, 2017.
Total revenue was $4.3 million for the second quarter as
compared to $2.8 million for the same period last year. Product
revenues of $4.1 million were up 61%, or $1.6 million, when
compared to the same period last year, as result of strong growth
in the United States, Europe, the rest of the world and Latin
America.
“Our revenue growth was powered by
significant year-over-year and quarter-over-quarter gains in
many of our top products including Alevicyn, Celacyn and
Mondoxyne,” said Jim Schutz, Sonoma Pharmceuticals CEO. “We believe
our results reflect the quality of our product line, the
excellent team we are building at Sonoma and that we are continuing
to deliver on our business strategy.”
Business Highlights:
- Robust portfolio of six non-steroidal products for treatment of
atopic and seborrheic dermatitis, surgical procedures, severe acne,
skin repair and descaling, and scar management.
- Loyon® skin descaling product, approved by the FDA in March
2017, was loaded into the wholesalers in September 2017 and will be
promoted by sales reps beginning in late November 2017.
- Company has 30 sales representatives and five sales managers,
focused exclusively on the dermatology prescription market.
- Received approval by Brazilian Ministério da Saúde for seven
non-steroidal and non-antibiotic, topical dermatology products in
October 2017.
Financial Highlights:Product revenues in the
United States for the three months ended September 30, 2017, of
$2.3 million, increased by $571,000, or 34%, as compared to $1.7
million for the three months ended September 30, 2016. This
increase was mostly the result of higher sales of the company’s
dermatology and acute care products, partly offset by a decline in
sales of animal health care products.
Product revenue in Europe and the rest of the world for the
three months ended September 30, 2017, of $1.1 million, increased
by $245,000, or 28%, as compared to $877,000 for the three months
ended September 30, 2016. This increase was mostly the result of
higher sales in Europe, China, Hong Kong, Singapore, and India
partly offset by a decrease in the Middle East.
Product revenue in Latin America for the quarter ended September
30, 2017, was $754,000. This amount reflects the sale of products
to Invekra, following completion of Sonoma’s asset sale to Invekra
in October 2016. Sonoma will continue to supply Invekra until its
manufacturing facility is operational.
Sonoma reported gross profit of $1.8 million, or 43% of total
revenue, during the three months ended September 30, 2017, compared
to a gross profit of $1 million, or 37% of total revenue when
compared to the same period in the prior year. The gross profit
percentage increased as compared to last year, primarily due to the
reclassification of gross margin between the continuing and
discontinued operations.
Total operating expenses of $4.7 million for the three months
ended September 30, 2017, increased by $683,000, or 17%, as
compared to the same period in the prior year. Operating expenses
minus non-cash expenses during the second quarter of fiscal year
2018 were $4.2 million, up $563,000, or 15%, as compared to the
same period in the prior year. This increase in operating expenses
was mostly due to higher sales, marketing and administrative
expenses in the United States related to the growth of a direct
sales force in dermatology, partly offset by a decline in European
expenses. A key driver to the growth in operating expenses is
the increase in the number of sales representatives, compared to
the same period last year.
Net loss from continuing operations for the quarter ended
September 30, 2017, was $2.9 million, an increase of $231,000, as
compared to net loss from continuing operations of $2.6 million for
the same period in the prior year. The operating loss minus
non-cash expenses was $2.3 million, down $260,000, compared to $2.5
million for the same period last year.
As of September 30, 2017, Sonoma had cash and
cash equivalents of $10 million, as compared with $12.6 million as
of June 30, 2017. The decline from June 30, 2017 consists primarily
of $2.3 million cash operating loss and an increase in net working
capital.
Results for the Six Months Ended September 30,
2017 Total revenues of $8.2
million increased by $2.7 million, or 50%, for the six months ended
September 30, 2017, as compared to $5.4 million for the six months
ended September 30, 2016. Product revenue of $7.7 million for the
six months ended September 30, 2017, increased $2.8 million, or
55%, compared to the same period last year. This increase in
product revenue was driven by strong growth in the United States,
up $1.1 million, or 34%, and Europe and rest of world, up
20%.
The company reported gross profit related to sales of its
products of $3.5 million, or 46% of total revenues, for the six
months ended September 30, 2017.
Total operating expenses less non-cash expenses of $8.9 million
increased $1.1 million, or 15%, for the six months end September
30, 2017, compared to the same period in the prior year. This
increase was primarily due to higher costs of the direct sales
force for dermatology. Operating loss less non-cash expenses
(EBITDA) for the six months ended September 30, 2017, was $5.1
million, compared to $5.6 million for the same period last
year.
Conference CallSonoma’s management will hold a
conference call today to discuss second quarter fiscal year 2018
results and answer questions, beginning at 4:30 p.m. EST.
Individuals interested in participating in the conference call may
do so by dialing 877-303-7607 for domestic callers or 973-638-3203
for international callers. Those interested in listening to the
conference call live via the Internet may do so at
http://ir.sonomapharma.com/events.cfm. Please log on
approximately 30 minutes prior to the presentation in order to
register and download the appropriate software. Also, participants
can download a graphical presentation of the quarterly results at
this same site, which can provide greater granular detail in
conjunction with the call.
A telephone replay will be available for seven days following
the conclusion of the call by dialing 855-859-2056 for domestic
callers, or 404-537-3406 for international callers, and entering
conference code 85466211. A webcast replay will be available on the
site at http://ir.sonomapharma.com/events.cfm for one year
following the call.
Sale of Latin American Business and Impact on Accounting
TreatmentWith the sale of the Latin American business
during the third quarter, ended December 31, 2016, the components
of the financial statements related to this transaction have been
classified as a discontinued business for accounting purposes and
in accordance with this accounting treatment, the income statement
and balance sheet have been retroactively revised to reflect the
revenue, expenses and balance sheet items of the continuing
businesses for this fiscal year and last fiscal year. All of the
income statement categories related to Latin America have been
condensed to a one line item on the income statement as “Income
from discontinued operations.” Also, the discontinued balance
sheets items have been listed separately from the continuing
operations. As a result, the comparison of results discussed in
this press release relate primarily to the continuing businesses in
accordance with generally accepted accounting principles.
About Sonoma Pharmaceuticals, Inc.Sonoma is a
specialty pharmaceutical company that develops and markets unique
and effective solutions for the treatment of dermatological
conditions and advanced tissue care. The company’s
products, which are sold throughout the United States and
internationally, have improved outcomes for more than five million
patients globally by reducing infections, itch, pain, scarring
and harmful inflammatory responses. The company's headquarters are
in Petaluma, California, with manufacturing operations in the
United States and Latin America. European marketing and sales
are headquartered in Roermond, Netherlands. More information can be
found at www.sonomapharma.com.
Forward-Looking StatementsExcept for historical
information herein, matters set forth in this press release
are forward-looking within the meaning of the “safe harbor”
provisions of the Private Securities Litigation Reform Act of 1995,
including statements about the commercial and technology progress
and future financial performance of Sonoma Pharmaceuticals,
Inc. and its subsidiaries (the “Company”). These forward-looking
statements are identified by the use of words such as “believe,”
“achieve,” and “strive,” among others. Forward-looking statements
in this press release are subject to certain risks and
uncertainties inherent in the Company’s business that could cause
actual results to vary, including such risks
that regulatory clinical and guideline developments may
change, scientific data may not be sufficient to meet
regulatory standards or receipt of required regulatory clearances
or approvals, clinical results may not be replicated in actual
patient settings, protection offered by the
Company’s patents and patent applications may be challenged,
invalidated or circumvented by its competitors, the available
market for the Company’s products will not be as
large as expected, the Company’s products will not be able to
penetrate one or more targeted markets, revenues will not be
sufficient to fund further development and clinical studies,
as well as uncertainties relative to varying product formulations
and a multitude of diverse regulatory and marketing requirements in
different countries and municipalities, and other risks detailed
from time to time in the Company’s filings with the Securities and
Exchange Commission. The Company disclaims any obligation to update
these forward-looking statements, except as required by law.
Sonoma Pharmaceuticals™, Alevicyn™, Celacyn®, Mondoxyne™ and
Microcyn® Technology are trademarks or registered trademarks of
Sonoma Pharmaceuticals, Inc. All other trademarks and service marks
are the property of their respective owners.
Media and Investor
Contact:
Sonoma Pharmaceuticals,
Inc.Dan McFaddenVP of Public and Investor
Relations(425) 753-2105dmcfadden@sonomapharma.com
SONOMA PHARMACEUTICALS, INC. AND
SUBSIDIARIESCondensed Consolidated Balance
Sheets(In thousands, except share and per share
amounts) |
|
|
|
September 30, |
|
|
March 31, |
|
|
|
2017 |
|
|
2017 |
|
|
|
(Unaudited) |
|
|
|
|
ASSETS |
|
|
|
|
|
|
|
|
Current assets: |
|
|
|
|
|
|
|
|
Cash and
cash equivalents |
|
$ |
9,983 |
|
|
$ |
17,461 |
|
Accounts
receivable, net |
|
|
3,035 |
|
|
|
2,108 |
|
Inventories, net |
|
|
2,603 |
|
|
|
2,221 |
|
Prepaid
expenses and other current assets |
|
|
1,331 |
|
|
|
616 |
|
Current
portion of deferred consideration, net of discount |
|
|
247 |
|
|
|
237 |
|
Total
current assets |
|
|
17,199 |
|
|
|
22,643 |
|
Property
and equipment, net |
|
|
1,358 |
|
|
|
1,239 |
|
Deferred
consideration, net of discount, less current portion |
|
|
1,501 |
|
|
|
1,497 |
|
Other
assets |
|
|
95 |
|
|
|
80 |
|
Total
assets |
|
$ |
20,153 |
|
|
$ |
25,459 |
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
|
|
|
|
|
Current
liabilities: |
|
|
|
|
|
|
|
|
Accounts
payable |
|
$ |
1,275 |
|
|
$ |
1,255 |
|
Accrued
expenses and other current liabilities |
|
|
1,391 |
|
|
|
1,302 |
|
Deferred
revenue |
|
|
199 |
|
|
|
345 |
|
Deferred
revenue Invekra |
|
|
151 |
|
|
|
176 |
|
Current
portion of long-term debt |
|
|
49 |
|
|
|
123 |
|
Current
portion of capital leases |
|
|
142 |
|
|
|
74 |
|
Taxes
payable |
|
|
– |
|
|
|
13 |
|
Total
current liabilities |
|
|
3,207 |
|
|
|
3,288 |
|
Long-term deferred
revenue Invekra |
|
|
531 |
|
|
|
527 |
|
Long-term debt, less
current portion |
|
|
39 |
|
|
|
45 |
|
Long-term capital
leases, less current portion |
|
|
216 |
|
|
|
168 |
|
Total
liabilities |
|
|
3,993 |
|
|
|
4,028 |
|
Commitments and
Contingencies |
|
|
|
|
|
|
|
|
Stockholders’
Equity |
|
|
|
|
|
|
|
|
Convertible preferred stock, $0.0001 par value; 714,286 shares
authorized, none issued and outstanding at September 30, 2017
and March 31, 2017, respectively |
|
|
– |
|
|
|
– |
|
Common
stock, $0.0001 par value; 12,000,000 shares authorized at September
30, 2017 and March 31, 2017, 4,323,831 and 4,289,322 shares
issued and outstanding at September 30, 2017 and March 31,
2017, respectively |
|
|
1 |
|
|
|
1 |
|
Additional paid-in capital |
|
|
169,672 |
|
|
|
168,709 |
|
Accumulated deficit |
|
|
(149,490 |
) |
|
|
(143,101 |
) |
Accumulated other comprehensive loss |
|
|
(4,023 |
) |
|
|
(4,178 |
) |
Total
stockholders’ equity |
|
|
16,160 |
|
|
|
21,431 |
|
Total
liabilities and stockholders’ equity |
|
$ |
20,153 |
|
|
$ |
25,459 |
|
|
|
|
|
|
|
|
|
|
SONOMA PHARMACEUTICALS, INC. AND
SUBSIDIARIESCondensed Consolidated Statements of
Comprehensive Loss(In thousands, except per share
amounts)(Unaudited) |
|
|
|
Three Months Ended September 30, |
|
|
Six Months Ended September 30, |
|
|
|
2017 |
|
|
2016 |
|
|
2017 |
|
|
2016 |
|
Revenues |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Product |
|
$ |
4,144 |
|
|
$ |
2,574 |
|
|
$ |
7,747 |
|
|
$ |
4,985 |
|
Service |
|
|
181 |
|
|
|
224 |
|
|
|
413 |
|
|
|
451 |
|
Total
revenues |
|
|
4,325 |
|
|
|
2,798 |
|
|
|
8,160 |
|
|
|
5,436 |
|
Cost of revenues |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Product |
|
|
2,308 |
|
|
|
1,558 |
|
|
|
4,221 |
|
|
|
3,030 |
|
Service |
|
|
169 |
|
|
|
204 |
|
|
|
329 |
|
|
|
389 |
|
Total
cost of revenues |
|
|
2,477 |
|
|
|
1,762 |
|
|
|
4,550 |
|
|
|
3,419 |
|
Gross profit |
|
|
1,848 |
|
|
|
1,036 |
|
|
|
3,610 |
|
|
|
2,017 |
|
Operating expenses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Research
and development |
|
|
368 |
|
|
|
379 |
|
|
|
750 |
|
|
|
739 |
|
Selling,
general and administrative |
|
|
4,337 |
|
|
|
3,643 |
|
|
|
9,100 |
|
|
|
7,773 |
|
Total
operating expenses |
|
|
4,705 |
|
|
|
4,022 |
|
|
|
9,850 |
|
|
|
8,512 |
|
Loss from
operations |
|
|
(2,857 |
) |
|
|
(2,986 |
) |
|
|
(6,240 |
) |
|
|
(6,495 |
) |
Interest expense |
|
|
(10 |
) |
|
|
(1 |
) |
|
|
(20 |
) |
|
|
(2 |
) |
Interest income |
|
|
18 |
|
|
|
1 |
|
|
|
71 |
|
|
|
2 |
|
Other (expense) income,
net |
|
|
(21 |
) |
|
|
(9 |
) |
|
|
(189 |
) |
|
|
(6 |
) |
Loss from continuing
operations before income taxes |
|
|
(2,870 |
) |
|
|
(2,995 |
) |
|
|
(6,378 |
) |
|
|
(6,501 |
) |
Income tax benefit |
|
|
– |
|
|
|
356 |
|
|
|
– |
|
|
|
675 |
|
Loss from continuing
operations |
|
|
(2,870 |
) |
|
|
(2,639 |
) |
|
|
(6,378 |
) |
|
|
(5,826 |
) |
Income from
discontinued operations (net of tax) |
|
|
– |
|
|
|
690 |
|
|
|
– |
|
|
|
1,309 |
|
Net loss |
|
$ |
(2,870 |
) |
|
$ |
(1,949 |
) |
|
$ |
(6,378 |
) |
|
$ |
(4,517 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per share:
basic and diluted |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Continuing operations |
|
$ |
(0.67 |
) |
|
$ |
(0.63 |
) |
|
$ |
(1.48 |
) |
|
$ |
(1.39 |
) |
Discontinued operations |
|
|
– |
|
|
|
0.17 |
|
|
|
– |
|
|
|
0.31 |
|
|
|
$ |
(0.67 |
) |
|
$ |
(0.46 |
) |
|
$ |
(1.48 |
) |
|
$ |
(1.08 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average number
of shares used in per share calculations: basic and diluted |
|
|
4,313 |
|
|
|
4,202 |
|
|
|
4,303 |
|
|
|
4,195 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other comprehensive
loss |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(2,870 |
) |
|
$ |
(1,949 |
) |
|
$ |
(6,378 |
) |
|
$ |
(4,517 |
) |
Foreign currency
translation adjustments |
|
|
(45 |
) |
|
|
(168 |
) |
|
|
155 |
|
|
|
(401 |
) |
Comprehensive loss |
|
$ |
(2,915 |
) |
|
$ |
(2,117 |
) |
|
$ |
(6,223 |
) |
|
$ |
(4,918 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SONOMA PHARMACEUTICALS, INC. AND
SUBSIDIARIESRECONCILIATION OF GAAP MEASURES TO
NON-GAAP MEASURES(In thousands) and (Unaudited) |
|
|
|
Three Months Ended September 30, |
|
|
Six Months Ended September 30, |
|
|
|
2017 |
|
|
2016 |
|
|
2017 |
|
|
2016 |
|
(1) Loss
from operations minus non-cash
expenses (EBITDA): |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP loss from
operations as reported |
|
$ |
(2,857 |
) |
|
$ |
(2,986 |
) |
|
$ |
(6,240 |
) |
|
$ |
(6,495 |
) |
|
Non-cash
adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock-based compensation |
|
|
462 |
|
|
|
406 |
|
|
|
900 |
|
|
|
817 |
|
|
Depreciation and amortization |
|
|
132 |
|
|
|
57 |
|
|
|
241 |
|
|
|
118 |
|
|
Non-GAAP
loss from operations minus non-cash expenses (EBITDA) |
|
$ |
(2,263 |
) |
|
$ |
(2,523 |
) |
|
$ |
(5,099 |
) |
|
$ |
(5,560 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(2) Net
loss minus non-cash expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP net loss as
reported |
|
$ |
(2,870 |
) |
|
$ |
(1,949 |
) |
|
$ |
(6,378 |
) |
|
$ |
(4,517 |
) |
|
Non-cash
adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock-based compensation |
|
|
462 |
|
|
|
406 |
|
|
|
900 |
|
|
|
817 |
|
|
Depreciation and amortization |
|
|
132 |
|
|
|
57 |
|
|
|
241 |
|
|
|
118 |
|
|
Gain due
to change in fair value of derivative instruments |
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
|
– |
|
|
Non-GAAP
net loss minus non-cash expenses |
|
$ |
(2,276 |
) |
|
$ |
(1,486 |
) |
|
$ |
(5,237 |
) |
|
$ |
(3,582 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(3)
Operating expenses minus non-cash
expenses |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
GAAP operating expenses
as reported |
|
$ |
4,705 |
|
|
$ |
4,022 |
|
|
$ |
9,850 |
|
|
$ |
8,512 |
|
|
Non-cash
adjustments: |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Stock-based compensation |
|
|
(413 |
) |
|
|
(340 |
) |
|
|
(807 |
) |
|
|
(683 |
) |
|
Depreciation and amortization |
|
|
(55 |
) |
|
|
(8 |
) |
|
|
(97 |
) |
|
|
(16 |
) |
|
Non-GAAP
operating expenses minus non-cash expenses |
|
$ |
4,237 |
|
|
$ |
3,674 |
|
|
$ |
8,946 |
|
|
$ |
7,813 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
Loss from
operations minus non-cash expenses (EBITDAS) is a non-GAAP
financial measure. The Company defines operating loss minus
non-cash expenses as GAAP reported operating loss minus operating
depreciation and amortization, and operating stock-based
compensation. The Company uses this measure for the purpose of
modifying the operating loss to reflect direct cash related
transactions during the measurement period. |
|
|
|
(2) |
|
Net loss
minus non-cash expenses is a non-GAAP financial measure. The
Company defines net loss minus non-cash expenses as GAAP reported
net loss minus depreciation and amortization, stock-based
compensation, and non-cash foreign exchange transaction losses. The
Company uses this measure for the purpose of modifying the net loss
to reflect only those expenses to reflect direct cash transactions
during the measurement period. |
|
|
|
(3) |
|
Operating
expenses minus non-cash expenses is a non-GAAP financial measure.
The Company defines operating expenses minus non-cash expenses as
GAAP reported operating expenses minus operating depreciation and
amortization, and operating stock-based compensation. The Company
uses this measure for the purpose of identifying total operating
expenses involving cash transactions during the measurement
period. |
|
|
|
SONOMA PHARMACEUTICALS, INC. AND
SUBSIDIARIESPRODUCT RELATED REVENUE
SCHEDULES(In thousands) and (Unaudited)
The following table shows the Company’s product
revenues by geographic region:
|
|
Three Months Ended September 30, |
|
|
|
|
|
|
|
|
|
2017 |
|
|
2016 |
|
|
$ Change |
|
|
% Change |
|
United States |
|
$ |
2,268 |
|
|
$ |
1,697 |
|
|
$ |
571 |
|
|
|
34 |
% |
|
Latin America |
|
|
754 |
|
|
|
– |
|
|
|
754 |
|
|
|
100 |
% |
|
Europe and Rest of the
World |
|
|
1,122 |
|
|
|
877 |
|
|
|
245 |
|
|
|
28 |
% |
|
Total |
|
$ |
4,144 |
|
|
$ |
2,574 |
|
|
$ |
1,570 |
|
|
|
61 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended September 30, |
|
|
|
|
|
|
|
|
|
2017 |
|
|
2016 |
|
|
$ Change |
|
|
% Change |
|
United States |
|
$ |
4,127 |
|
|
$ |
3,070 |
|
|
$ |
1,057 |
|
|
|
34 |
% |
|
Latin America |
|
|
1,323 |
|
|
|
– |
|
|
|
1,323 |
|
|
|
100 |
% |
|
Europe and Rest of the
World |
|
|
2,297 |
|
|
|
1,915 |
|
|
|
382 |
|
|
|
20 |
% |
|
Total |
|
$ |
7,747 |
|
|
$ |
4,985 |
|
|
$ |
2,762 |
|
|
|
55 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
In connection with the Company’s sale of its
Latin America business to Invekra, product related revenues were
reclassified from continuing operations to discontinued
operations. The amounts were classified in the prior periods
as Latin America sales. The amounts reclassified are as
follows:
|
|
Three Months Ended September 30, |
|
|
|
2017 |
|
|
2016 |
|
Product revenues |
|
$ |
– |
|
|
$ |
1,235 |
|
Product license fees
and royalties |
|
|
– |
|
|
|
76 |
|
Total product related
revenues |
|
$ |
– |
|
|
$ |
1,311 |
|
|
|
|
|
|
|
|
|
|
|
|
Six Months Ended September 30, |
|
|
|
2017 |
|
|
2016 |
|
Product revenues |
|
$ |
– |
|
|
$ |
2,333 |
|
Product license fees
and royalties |
|
|
– |
|
|
|
151 |
|
Total product related
revenues |
|
$ |
– |
|
|
$ |
2,484 |
|
|
|
|
|
|
|
|
|
|
Sonoma Pharmaceuticals (NASDAQ:SNOAW)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sonoma Pharmaceuticals (NASDAQ:SNOAW)
Historical Stock Chart
From Jul 2023 to Jul 2024